Midas Letter
Midas Letter
Most Undervalued Weed Stocks

Weed stocks still represent a massive viable investment opportunity. The industry is still in its infancy stage but still has a long way to grow. The industry has seen significant growth in the last year, where a handful of companies have emerged as country or state leaders. Today’s interview searches for the weed stocks trading under their fair price and is most undervalued.

Most of those opportunities are in the US, where MSOs have seen significant revenue growth and EBITDA in the last couple of years. On the other hand, Canada has seen negative EBITDA growth with its administrative backlog and other regulatory hurdles.

Some companies are bucking this trend, however—companies with differentiated strategies to grow the cheapest plants.

“What we see as a trend is really 2 things in Canada. The Value trend – part of the reason the large LPs haven’t been able to really perform very well. The second trend is Premium” – StoneCastle Investment Portfolio Manager Bruce Campbell

Watch the full interview for the most undervalued weed stocks today, premium cannabis vs value cannabis, and how the black market affects the legal market.


00:53 – Becoming Plant-Based Investment Corp (OTCMKTS:CWWBF, CNSX:PBIC) CIO
01:47 – Portfolio performance in last year
02:30 – Top weed stock holdings
03:53 – MSO vs Canadian LPs & GTEC Holdings Ltd (OTCMKTS:GGTTF, CVE:GTEC)
05:56 – Premium cannabis vs value cannabis
06:51 – Canadian black market impact
08:23 – US black market impact
09:53 – US decriminalization


Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.